LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT

被引：0

作者：

De la Rubia Navarro, M. ^{[1
]}

Cortes, J. Ivorra ^{[1
]}

Garcia, E. Grau ^{[1
]}

Puig, L. Gonzalez ^{[1
]}

Albuixech, R. Negueroles ^{[1
]}

Cordellat, I. Martinez ^{[1
]}

Ortiz-Sanjuan, F. ^{[1
]}

Rodriguez, J. E. Oller ^{[1
]}

Rodriguez, S. Leal ^{[1
]}

Perales, C. Pavez ^{[1
]}

Gil, J. J. Fragio ^{[1
]}

Bernabeu, E. Vicens ^{[1
]}

Barcena, C. Riesco ^{[1
]}

Quispe, A. V. Huaylla ^{[1
]}

Sanchez, L. Mas ^{[1
]}

Munoz, P. ^{[1
]}

Herranz, C. Najera ^{[1
]}

Olmos, I. Canovas ^{[1
]}

Ivorra, J. A. Roman ^{[1
]}

机构：

[1] Hosp Univ La Fe, Reumatol, Valencia, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷

关键词：

D O I：

10.1136/annrheumdis-2022-eular.2944

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0435

引用

页码：1345 / 1346

页数：2

共 50 条

[31] SERUM ANEXELEKTO (AXL) AS A NOVEL BIOMARKER OF RENAL ACTIVITY, TREATMENT RESPONSE AND LONG-TERM OUTCOME IN PATIENTS WITH LUPUS NEPHRITIS
Parodis, I.
Ding, H.
Zickert, A.
Arnaud, L.
Mohan, C.
Gunnarsson, I.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S69 - S69
[32] Serum anexelekto (Axl) as a novel biomarker of renal activity, treatment response, and long-term outcome in patients with lupus nephritis
Parodis, I.
Ding, H.
Zickert, A.
Arnaud, L.
Mohan, C.
Gunnarsson, I.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 43 - 44
[33] CHANGES IN SERUM AND URINE LYSOZYME ACTIVITY AFTER KIDNEY-TRANSPLANTATION - INFLUENCE OF GRAFT FUNCTION AND THERAPY WITH AZATHIOPRINE
HORPACSY, G
ZINSMEYER, J
SCHRODER, K
MEBEL, M
CLINICAL CHEMISTRY, 1978, 24 (01) : 74 - 79
[34] Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients
Huang Dedong
Zhu Feiyan
Shi Jie
Lai Xiaowei
Wang Shaoyang
IMMUNOLOGY LETTERS, 2019, 210 : 33 - 39
[35] Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients
Studenic, Paul
Alasti, Farideh
Smolen, Josef S.
Haslacher, Helmuth
Aletaha, Daniel
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[36] Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis
Ganguly, Sujata
Majumder, Sanjukta
Muhammed, Hafis
Aggarwal, Amita
Misra, Ramnath
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[37] URINE-GALECTINE 3 BINDING PROTEIN (U-GAL3BP) IS A SENSITIVE MARKER OF KIDNEY INFLAMMATION AND RESPONSE TO TREATMENT IN LUPUS
Faustini, F.
Idborg, H.
Svenungsson, E.
Poetzsch, S.
Okitsu, S.
Larsson, A.
Gunnarsson, I.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 305 - 306
[38] Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa
Mothusi W. Moloi
Jody A. Rusch
Fierdoz Omar
Udeme Ekrikpo
Collet Dandara
Aminu K. Bello
David Jayne
Ikechi G. Okpechi
International Urology and Nephrology, 2021, 53 : 1865 - 1873
[39] Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa
Moloi, Mothusi W.
Rusch, Jody A.
Omar, Fierdoz
Ekrikpo, Udeme
Dandara, Collet
Bello, Aminu K.
Jayne, David
Okpechi, Ikechi G.
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (09) : 1865 - 1873
[40] Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
Davies, Jennifer C.
Midgley, Angela
Carlsson, Emil
Donohue, Sean
Bruce, Ian N.
Beresford, Michael W.
Hedrich, Christian M.
RMD OPEN, 2020, 6 (02):

← 1 2 3 4 5 →